Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
FibroBiologics Inc. (FBLG) had Return on Tangible Equity of -302.89% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-18.65M |
|
-- |
|
-- |
|
$16.65M |
|
$-16.65M |
|
$-2.00M |
|
$-18.65M |
|
$-18.65M |
|
$-18.65M |
|
$-18.65M |
|
$-18.65M |
|
$-18.65M |
|
$-16.65M |
|
$-15.82M |
|
2.23M |
|
2.23M |
|
$-8.40 |
|
$-8.40 |
|
| Balance Sheet Financials | |
$6.35M |
|
$0.84M |
|
$3.27M |
|
$9.62M |
|
$1.76M |
|
-- |
|
$1.70M |
|
$3.46M |
|
$6.16M |
|
$6.16M |
|
$6.16M |
|
3.33M |
|
| Cash Flow Statement Financials | |
$-16.39M |
|
$-0.26M |
|
$7.57M |
|
$13.98M |
|
$4.89M |
|
$-9.09M |
|
$2.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.61 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.66M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-302.89% |
|
|
Return on Tangible Equity |
-302.89% |
-193.85% |
|
-302.89% |
|
$1.85 |
|
$-7.46 |
|
$-7.34 |
|